Abstract

Aims Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60-70% of patients admitted with acute coronary syndromes in clinical practice. This study provides a 'real-life' overview of NSTE-ACS patient characteristics, dual antiplatelet therapy clinical practice, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge. Methods and results A total of 10 registries (documenting 84 054 NSTE-ACS patients) provided data in a systematic manner on patient characteristics and outcomes for NSTE-ACS in general, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-Analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry). Conclusions There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short-And long-Term ischaemic and bleeding events. In future registries, data collection should be performed in a more standardized way with respect to endpoints, definitions, and time points.

Original languageEnglish
Pages (from-to)229-243
Number of pages15
JournalEuropean Heart Journal - Cardiovascular Pharmacotherapy
Volume2
Issue number4
DOIs
Publication statusPublished - 2016 Oct 1

Subject classification (UKÄ)

  • Cardiac and Cardiovascular Systems

Free keywords

  • Acute coronary syndromes
  • Antiplatelets
  • Clopidogrel
  • Non-ST-segment elevation
  • Observational
  • P2Y12 receptor inhibitors
  • Prasugrel
  • Ticagrelor

Fingerprint

Dive into the research topics of 'P2Y12 receptor inhibitors in patients with non-STelevation acute coronary syndrome in the real world: Use, patient selection, and outcomes from contemporary European registries'. Together they form a unique fingerprint.

Cite this